During the last session, Ocugen Inc. (NASDAQ:OCGN)’s traded shares were 7.95 million, with the beta value of the company hitting 4.42. At the end of the trading day, the stock’s price was $2.54, reflecting an intraday gain of 7.17% or $0.17. The 52-week high for the OCGN share is $17.65, that puts it down -594.88 from that peak though still a striking 34.25% gain since the share price plummeted to a 52-week low of $1.67. The company’s market capitalization is $494.49M, and the average intraday trading volume over the past 10 days was 7.67 million shares, and the average trade volume was 7.27 million shares over the past three months.
Ocugen Inc. (OCGN) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.50. OCGN has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.01.
Ocugen Inc. (NASDAQ:OCGN) trade information
Ocugen Inc. (OCGN) registered a 7.17% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.17% in intraday trading to $2.54 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 22.12%, and it has moved by 15.98% in 30 days. Based on these gigs, the overall price performance for the year is -66.40%. The short interest in Ocugen Inc. (NASDAQ:OCGN) is 58.6 million shares and it means that shorts have 8.38 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.60, which implies an increase of 66.58% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.50 and $15.00 respectively. As a result, OCGN is trading at a discount of -490.55% off the target high and -37.8% off the low.
Ocugen Inc. (OCGN) estimates and forecasts
Statistics show that Ocugen Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Ocugen Inc. (OCGN) shares have gone down -53.48% during the last six months, with a year-to-date growth rate less than the industry average at -13.33% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 92.30% this quarter and then jump 100.00% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 65.20%. While earnings are projected to return 2.30% in 2022.
Ocugen Inc. is due to release its next quarterly earnings between March 16 and March 21. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ocugen Inc. (NASDAQ:OCGN)’s Major holders
Ocugen Inc. insiders own 1.59% of total outstanding shares while institutional holders control 37.83%, with the float percentage being 38.44%. State Street Corporation is the largest shareholder of the company, while 185 institutions own stock in it. As of Dec 30, 2021, the company held over 14.02 million shares (or 6.50% of all shares), a total value of $63.78 million in shares.
The next largest institutional holding, with 12.16 million shares, is of Blackrock Inc.’s that is approximately 5.64% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $40.14 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ocugen Inc. (OCGN) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Jan 30, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 11.53 million shares. This amounts to just over 5.35 percent of the company’s overall shares, with a $40.94 million market value. The same data shows that the other fund manager holds slightly less at 5.6 million, or about 2.60% of the stock, which is worth about $25.49 million.